Your browser is no longer supported. Please, upgrade your browser.
AGIO Agios Pharmaceuticals, Inc. daily Stock Chart
AGIO [NASD]
Agios Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-6.85 Insider Own2.90% Shs Outstand65.69M Perf Week14.07%
Market Cap3.07B Forward P/E- EPS next Y-6.56 Insider Trans31.07% Shs Float59.32M Perf Month36.07%
Income-400.90M PEG- EPS next Q-1.75 Inst Own94.90% Short Float15.63% Perf Quarter23.84%
Sales112.50M P/S27.27 EPS this Y10.80% Inst Trans2.75% Short Ratio10.52 Perf Half Y-7.82%
Book/sh7.62 P/B6.13 EPS next Y6.40% ROA-50.70% Target Price64.55 Perf Year-12.30%
Cash/sh6.88 P/C6.79 EPS next 5Y40.00% ROE-70.10% 52W Range28.36 - 68.94 Perf YTD1.28%
Dividend- P/FCF- EPS past 5Y-16.40% ROI- 52W High-32.26% Beta2.30
Dividend %- Quick Ratio5.20 Sales past 5Y29.90% Gross Margin98.50% 52W Low64.67% ATR2.06
Employees482 Current Ratio5.30 Sales Q/Q71.10% Oper. Margin- RSI (14)83.09 Volatility6.61% 4.77%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.70% Profit Margin- Rel Volume0.70 Prev Close45.70
ShortableYes LT Debt/Eq0.00 EarningsOct 31 BMO Payout- Avg Volume881.40K Price46.70
Recom1.80 SMA2019.22% SMA5031.60% SMA2001.32% Volume621,332 Change2.19%
Nov-26-19Initiated Cantor Fitzgerald Overweight $64
Sep-23-19Upgrade Guggenheim Neutral → Buy $55
May-23-19Resumed Goldman Neutral $55
Feb-15-19Upgrade SVB Leerink Mkt Perform → Outperform $80
Sep-25-18Initiated Leerink Partners Mkt Perform
May-23-18Initiated Citigroup Buy $117
Apr-11-18Reiterated Credit Suisse Outperform $80 → $95
Feb-15-18Reiterated SunTrust Buy $80 → $101
Feb-15-18Reiterated Needham Buy $72 → $86
Sep-15-17Initiated RBC Capital Mkts Outperform $78
Aug-10-17Reiterated Needham Buy $54 → $72
Aug-08-17Reiterated SunTrust Buy $68 → $80
Aug-02-17Upgrade Leerink Partners Mkt Perform → Outperform $80
Jun-26-17Downgrade Janney Buy → Neutral
Jan-17-17Upgrade Oppenheimer Perform → Outperform
Oct-24-16Initiated Needham Buy $60
Jun-13-16Upgrade JP Morgan Neutral → Overweight
May-18-16Reiterated SunTrust Buy $57 → $65
May-18-16Reiterated Sun Trust Rbsn Humphrey Buy $57 → $65
Mar-30-16Initiated Sun Trust Rbsn Humphrey Buy $57
Dec-13-19 08:40AM  These Hedge Funds Cashed Out Of Agios Pharmaceuticals Inc (AGIO) Too Early Insider Monkey
04:25AM  Edited Transcript of AGIO earnings conference call or presentation 14-Feb-18 1:00pm GMT Thomson Reuters StreetEvents
Dec-09-19 04:19PM  Here Are The Winners From The Year's Biggest Hematology Meeting Investor's Business Daily
10:00AM  Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency GlobeNewswire
08:00AM  Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) GlobeNewswire
Dec-08-19 09:00AM  Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results GlobeNewswire
Dec-02-19 07:00AM  Agios Appoints Bruce Car, Ph.D., as Chief Scientific Officer GlobeNewswire
Nov-28-19 08:10AM  Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag Zacks
Nov-25-19 07:00AM  Agios Appoints Jonathan Biller as Chief Legal Officer GlobeNewswire
Nov-22-19 04:00PM  Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma GlobeNewswire
Nov-17-19 08:42AM  The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down Benzinga
Nov-14-19 07:11AM  3 Strong Buy Stocks to Buy on Weakness TipRanks
Nov-13-19 10:21AM  Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Nov-07-19 09:17PM  Agios Announces Pricing of $256 Million Public Offering of Common Stock GlobeNewswire
Nov-06-19 04:01PM  Agios Announces Proposed Offering of Common Stock GlobeNewswire
12:19PM  Edited Transcript of AGIO earnings conference call or presentation 31-Oct-19 12:00pm GMT Thomson Reuters StreetEvents
09:28AM  Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual Meeting GlobeNewswire
Nov-01-19 12:07PM  Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss Zacks +11.84%
07:38AM  The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance Benzinga
Oct-31-19 08:55AM  Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Misses Revenue Estimates Zacks
08:08AM  The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut Benzinga
07:00AM  Agios Reports Business Highlights and Third Quarter 2019 Financial Results GlobeNewswire
06:00AM  Agios Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-30-19 07:22PM  Agios Pharmaceuticals Inc (AGIO) Is Burning These Hedge Funds Insider Monkey
Oct-27-19 11:50AM  Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors GlobeNewswire
Oct-24-19 10:32AM  Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-17-19 07:00AM  Agios to Webcast Conference Call of Third Quarter 2019 Financial Results on October 31, 2019 GlobeNewswire
Oct-09-19 07:00AM  Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference GlobeNewswire
Oct-02-19 12:00PM  3 Pharma Stocks at Risk for Downgrades Schaeffer's Investment Research
11:36AM  Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study Zacks
Sep-30-19 10:30AM  Data from Agios Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients GlobeNewswire -5.95%
06:30AM  Biotech IPOs Are Risky Business. Heres How toDo a Deal Right. Barrons.com
Sep-10-19 07:00AM  Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO GlobeNewswire +6.21%
Sep-04-19 07:12PM  Edited Transcript of AGIO earnings conference call or presentation 1-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
05:00PM  Agios Announces Publication of Data for Mitapivat from Core and Extension Phases of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency in the New England Journal of Medicine GlobeNewswire
Aug-31-19 09:32AM  Agios Pharmaceuticals (AGIO) Down 11.2% Since Last Earnings Report: Can It Rebound? Zacks
Aug-29-19 04:05PM  Agios to Present at the Citi 14th Annual Biotech Conference on Thursday, September 5, 2019 GlobeNewswire
Aug-15-19 10:30AM  Agios Rides High on Tibsovo Sales Amid Acute Competition Zacks
Aug-09-19 09:24AM  An Intrinsic Calculation For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Suggests It's 50% Undervalued Simply Wall St.
Aug-05-19 11:15PM  Agios Pharmaceuticals Inc (AGIO) Q2 2019 Earnings Call Transcript Motley Fool -6.63%
Aug-01-19 12:02PM  Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales Zacks -11.16%
08:55AM  Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:00AM  Agios Reports Business Highlights and Second Quarter 2019 Financial Results GlobeNewswire
Jul-25-19 10:34AM  Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-18-19 07:00AM  Agios to Webcast Conference Call of Second Quarter 2019 Financial Results on August 1, 2019 GlobeNewswire
Jul-01-19 07:00AM  Agios Announces Orlando Oliveira Appointed as Senior Vice President and General Manager, International GlobeNewswire
Jun-18-19 08:40AM  Agios (AGIO) Catches Eye: Stock Jumps 5.4% Zacks
Jun-17-19 09:59AM  Volatility 101: Should Agios Pharmaceuticals (NASDAQ:AGIO) Shares Have Dropped 50%? Simply Wall St. +5.43%
Jun-14-19 06:28PM  Is Agios Pharmaceuticals Inc (AGIO) Going to Burn These Hedge Funds? Insider Monkey
Jun-10-19 01:12PM  Agios to Present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019 GlobeNewswire
Jun-06-19 09:17AM  Life sciences VC firm Third Rock raises $770M in its largest round ever American City Business Journals
Jun-05-19 04:00PM  Agios Announces the Planned Retirement of Chief Scientific Officer, Scott Biller, Ph.D., Effective December 31, 2019 GlobeNewswire
Jun-03-19 08:00AM  Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy GlobeNewswire
Jun-01-19 09:31AM  Agios Pharmaceuticals (AGIO) Down 8% Since Last Earnings Report: Can It Rebound? Zacks
May-16-19 10:49AM  Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study Zacks +5.05%
07:40AM  The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics Benzinga
May-15-19 11:39PM  Alibaba, Cisco, Agios Pharmaceuticals and More: Why These Stocks Are in the Spotlight Insider Monkey
05:41PM  Stocks making the biggest moves after hours: Agios, Farfetch, Cisco and more CNBC
04:05PM  Agios to Present Clinical Data from its IDH Program at ASCO GlobeNewswire
04:01PM  Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients GlobeNewswire
May-09-19 03:56AM  Edited Transcript of AGIO earnings conference call or presentation 2-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-03-19 10:19AM  Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1 Zacks +6.62%
May-02-19 02:59PM  Agios Pharmaceuticals Inc (AGIO) Q1 2019 Earnings Call Transcript Motley Fool
01:18PM  Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy GlobeNewswire
10:15AM  Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates Zacks
09:03AM  Agios Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM  Agios Reports Business Highlights and First Quarter 2019 Financial Results GlobeNewswire
06:00AM  Agios Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Apr-27-19 09:21AM  Did Hedge Funds Drop The Ball On Agios Pharmaceuticals Inc (AGIO)? Insider Monkey
Apr-26-19 10:30AM  Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline Zacks
Apr-25-19 04:00PM  Agios to Webcast Conference Call of First Quarter 2019 Financial Results on May 2, 2019 GlobeNewswire
Apr-11-19 03:27PM  What Are Analysts Saying About Agios Pharmaceuticals, Inc.'s (NASDAQ:AGIO) Earnings Outlook? Simply Wall St.
Apr-02-19 04:00PM  Agios Announces New Commercial Leadership Structure GlobeNewswire
10:09AM  AVEO Reports Positive Results on Leukemia Drug, Shares Up Zacks
Mar-27-19 10:48AM  Agios (AGIO) Surges More Than 40% Year to Date: Here's Why Zacks
10:45AM  Agios Gains Breakthrough Therapy Status for Tibsovo Combo Zacks
Mar-26-19 04:00PM  Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy GlobeNewswire +5.07%
Mar-16-19 09:30AM  Why Is Agios Pharmaceuticals (AGIO) Up 13.2% Since Last Earnings Report? Zacks
Mar-06-19 02:01PM  All You Need To Know About Agios Pharmaceuticals, Inc.s (NASDAQ:AGIO) Financial Health Simply Wall St. -6.11%
Mar-04-19 07:00AM  Agios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019 GlobeNewswire
Feb-25-19 07:00AM  Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia (AML) Patients GlobeNewswire +5.93%
Feb-22-19 07:25AM  Analysis: Positioning to Benefit within Quest Diagnostics, Autodesk, Agios Pharmaceuticals, AMN Healthcare Services, Vistra Energy, and Helen of Troy Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-21-19 09:34AM  Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer Zacks
07:00AM  Agios to Present at the Leerink Global Healthcare Conference on Thursday, February 28, 2019 GlobeNewswire
Feb-20-19 03:43PM  Edited Transcript of AGIO earnings conference call or presentation 14-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
07:00AM  Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy GlobeNewswire
Feb-15-19 02:25PM  Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock Zacks
Feb-14-19 12:01PM  Agios Pharmaceuticals Inc (AGIO) Q4 2018 Earnings Conference Call Transcript Motley Fool +6.27%
09:10AM  Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates Zacks
08:10AM  Agios Pharmaceuticals: 4Q Earnings Snapshot Associated Press
07:00AM  Agios Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-11-19 12:09PM  Agios ex-CEO joins GV as life sciences investment team's co-head American City Business Journals
Feb-07-19 10:31AM  Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jan-29-19 01:52PM  Have Insiders Been Selling Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares? Simply Wall St.
Jan-10-19 12:07PM  5 Biotech Stocks That Could Face M&A Next! InvestorPlace
Jan-07-19 07:00AM  Agios Highlights Key 2019 Initiatives to Broaden Potential for Cancer and Rare Genetic Disease Programs to Build Long-Term Value GlobeNewswire +8.70%
Dec-28-18 07:00AM  Agios to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 GlobeNewswire
Dec-14-18 12:03PM  Our Take On Agios Pharmaceuticals, Inc.s (NASDAQ:AGIO) CEO Salary Simply Wall St.
Dec-13-18 07:20AM  Market Trends Toward New Normal in DXC Technology, Patterson Companies, Lumentum, DSW, Agios Pharmaceuticals, and Six Flags Entertainment Corporation New Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
03:20AM  Hedge Funds Are Selling Agios Pharmaceuticals Inc (AGIO) Insider Monkey
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOUSE JACQUALYN AChief Executive OfficerNov 13Buy31.0040,3221,249,98241,722Nov 15 04:05 PM
Schenkein David PDirectorNov 13Buy31.008,064249,98497,567Nov 15 04:03 PM
CELGENE CORP /DE/10% OwnerNov 12Buy31.00403,22512,499,9751,777,824Nov 14 04:06 PM
Biller ScottChief Scientific OfficerJun 11Option Exercise2.347,21816,87233,729Jun 13 04:07 PM
Biller ScottChief Scientific OfficerApr 05Option Exercise39.763,000119,28029,511Apr 09 04:59 PM
Biller ScottChief Scientific OfficerApr 05Sale67.713,000203,13526,511Apr 09 04:59 PM
Bowden ChristopherChief Medical OfficerApr 01Option Exercise35.1610,000351,60017,238Apr 03 04:12 PM
Bowden ChristopherChief Medical OfficerApr 01Sale66.5710,000665,7477,238Apr 03 04:12 PM
Bowden ChristopherChief Medical OfficerMar 15Option Exercise35.1610,000351,60017,238Mar 19 04:25 PM
Bowden ChristopherChief Medical OfficerMar 15Sale64.1610,000641,6157,238Mar 19 04:25 PM
Biller ScottChief Scientific OfficerMar 05Option Exercise38.603,000115,80529,511Mar 07 04:06 PM
Biller ScottChief Scientific OfficerMar 05Sale67.683,000203,03226,511Mar 07 04:06 PM
Hoerter Steven L.Chief Commercial OfficerMar 04Option Exercise39.765,000198,80015,941Mar 05 04:04 PM
Hoerter Steven L.Chief Commercial OfficerMar 04Sale68.005,000340,00010,941Mar 05 04:04 PM
Hoerter Steven L.Chief Commercial OfficerMar 01Option Exercise39.765,000198,80015,941Mar 05 04:04 PM
Hoerter Steven L.Chief Commercial OfficerMar 01Sale66.015,000330,05010,941Mar 05 04:04 PM
Biller ScottChief Scientific OfficerFeb 27Option Exercise15.109,000135,87535,511Mar 01 04:02 PM
Biller ScottChief Scientific OfficerFeb 27Sale65.009,000585,00026,511Mar 01 04:02 PM
Biller ScottChief Scientific OfficerDec 21Option Exercise2.3420,50047,91924,637Dec 26 04:39 PM